YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (1558.HK)
HKD 12.66
(2.76%)
HKD 12.66
(2.76%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 934.91 Million CNY | -67.74% |
| 2022 | 2.89 Billion CNY | 40.53% |
| 2021 | 2.06 Billion CNY | 113.57% |
| 2020 | 965.69 Million CNY | 277.04% |
| 2019 | 256.12 Million CNY | 147.4% |
| 2018 | -540.34 Million CNY | 37.69% |
| 2017 | -867.18 Million CNY | 22.72% |
| 2016 | -1.12 Billion CNY | 3.16% |
| 2015 | -1.15 Billion CNY | -452.77% |
| 2014 | 328.44 Million CNY | -66.34% |
| 2013 | 975.67 Million CNY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 545 Million CNY | -12.7% |
| 2023 Q2 | 698.06 Million CNY | -75.91% |
| 2023 Q4 | 934.91 Million CNY | 33.93% |
| 2023 FY | 934.91 Million CNY | -67.74% |
| 2022 Q2 | 2.69 Billion CNY | 30.83% |
| 2022 FY | 2.89 Billion CNY | 40.53% |
| 2022 Q4 | 2.89 Billion CNY | 7.42% |
| 2021 Q4 | 2.06 Billion CNY | 17.31% |
| 2021 Q2 | 1.75 Billion CNY | 82.05% |
| 2021 FY | 2.06 Billion CNY | 113.57% |
| 2020 FY | 965.69 Million CNY | 277.04% |
| 2020 Q2 | -38.55 Million CNY | -115.05% |
| 2020 Q4 | 965.69 Million CNY | 2604.58% |
| 2019 FY | 256.12 Million CNY | 147.4% |
| 2019 Q2 | 324.37 Million CNY | 160.03% |
| 2019 Q4 | 256.12 Million CNY | -21.04% |
| 2018 Q4 | -540.34 Million CNY | 59.55% |
| 2018 Q2 | -1.33 Billion CNY | -54.05% |
| 2018 FY | -540.34 Million CNY | 37.69% |
| 2017 Q2 | -898.09 Million CNY | 19.96% |
| 2017 FY | -867.18 Million CNY | 22.72% |
| 2017 Q4 | -867.18 Million CNY | 3.44% |
| 2016 FY | -1.12 Billion CNY | 3.16% |
| 2016 Q2 | -1.34 Billion CNY | -16.3% |
| 2016 Q4 | -1.12 Billion CNY | 16.73% |
| 2015 Q2 | -244.71 Million CNY | -174.51% |
| 2015 Q4 | -1.15 Billion CNY | -373.48% |
| 2015 FY | -1.15 Billion CNY | -452.77% |
| 2014 FY | 328.44 Million CNY | -66.34% |
| 2014 Q4 | 328.44 Million CNY | 0.0% |
| 2013 FY | 975.67 Million CNY | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Pak Fah Yeow International Limited | -258.7 Million HKD | 461.385% |
| Grand Pharmaceutical Group Limited | 2.03 Billion HKD | 53.987% |
| Extrawell Pharmaceutical Holdings Limited | 5.94 Million HKD | -15628.718% |
| Wai Yuen Tong Medicine Holdings Limited | 301.53 Million HKD | -210.051% |
| Qianhai Health Holdings Limited | -19.03 Million HKD | 5010.784% |
| Lee's Pharmaceutical Holdings Limited | 30.94 Million HKD | -2920.922% |
| Essex Bio-Technology Limited | -219.22 Million HKD | 526.456% |
| Tongfang Kontafarma Holdings Limited | 256.16 Million HKD | -264.967% |
| PuraPharm Corporation Limited | 377.54 Million HKD | -147.627% |
| SSY Group Limited | 1.71 Billion HKD | 45.439% |
| JBM (Healthcare) Limited | -7.39 Million HKD | 12735.694% |
| Jacobson Pharma Corporation Limited | 337.44 Million HKD | -177.059% |
| China Resources Pharmaceutical Group Limited | 50.97 Billion HKD | 98.166% |